Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new...
Hence then, the article about new phase 3b data on lilly s taltz ixekizumab and zepbound tirzepatide advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity )
Also on site :
- Viola Davis, 61, Opens Up About ‘Extremely Painful’ Health Condition for the First Time: ‘It Terrified Me’ (Exclusive)
- In 1924, Caesar Cardini ran out of kitchen supplies in a Fourth of July rush at his Tijuana restaurant; he tossed romaine with what was left, and the salad carries his name
- Rosalía Shuts Down Kenan Thompson’s Idea for a Pop-Classical Album in Hilarious ‘SNL’ Promo: ‘That’s LUX’